Herpes simplex viruses: is a vaccine tenable?
作者信息
Whitley Richard J, Roizman Bernard
机构信息
Department of Pediatrics, Microbiology and Medicine, University of Alabama at Birmingham, 35233, USA.
出版信息
J Clin Invest. 2002 Jul;110(2):145-51. doi: 10.1172/JCI16126.
Abstract
摘要
相似文献
1
Herpes simplex viruses: is a vaccine tenable?
J Clin Invest. 2002 Jul;110(2):145-51. doi: 10.1172/JCI16126.
2
Genetically engineered herpes simplex virus vaccines.
Prog Med Virol. 1985;31:84-108.
3
[Herpes vaccines].
Vopr Virusol. 1987 May-Jun;32(3):261-77.
4
Herpes simplex virus vaccines.
Antiviral Res. 1985;Suppl 1:259-65. doi: 10.1016/s0166-3542(85)80036-x.
5
[Design of inactivated polyvalent antiherpes vaccines].
Vopr Virusol. 1979 Nov-Dec(6):665-71.
6
Prospects for vaccination against herpes simplex virus.
Pediatr Ann. 1993 Dec;22(12):726, 729-32. doi: 10.3928/0090-4481-19931201-08.
7
Expression and stability of herpes simplex virus antigens in Salmonella typhimurium.
Adv Exp Med Biol. 1995;371B:1543-6.
8
Herpes simplex vaccines.
Biotechnology. 1992;20:223-54. doi: 10.1016/b978-0-7506-9265-6.50016-6.
9
Vaccinia virus recombinants as potential herpes simplex virus vaccines.
Adv Exp Med Biol. 1992;327:183-9. doi: 10.1007/978-1-4615-3410-5_20.
10
[Toward the control of herpes simplex virus infections].
Uirusu. 2003 Jun;53(1):81-5. doi: 10.2222/jsv.53.81.
引用本文的文献
1
Differentially expressed genes during spontaneous lytic switch of Marek's disease virus in lymphoblastoid cell lines determined by global gene expression profiling.
J Gen Virol. 2017 Apr;98(4):779-790. doi: 10.1099/jgv.0.000744.
2
Cultured corneas show dendritic spread and restrict herpes simplex virus infection that is not observed with cultured corneal cells.
Sci Rep. 2017 Feb 15;7:42559. doi: 10.1038/srep42559.
3
Vaccines in Dermatology.
Indian J Dermatol. 2015 May-Jun;60(3):276-9. doi: 10.4103/0019-5154.156378.
4
Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum.
J Allergy Clin Immunol. 2014 Oct;134(4):848-55. doi: 10.1016/j.jaci.2014.07.018. Epub 2014 Aug 23.
5
An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge.
PLoS One. 2014 Jul 17;9(7):e100844. doi: 10.1371/journal.pone.0100844. eCollection 2014.
6
Towards an effective genital herpes vaccine: past lessons and future prospects.
Future Virol. 2007 Jan 1;2(1):1-6. doi: 10.2217/17460794.2.1.1.
7
Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.
PLoS One. 2013 Jun 6;8(6):e65523. doi: 10.1371/journal.pone.0065523. Print 2013.
8
The challenge of developing a herpes simplex virus 2 vaccine.
Expert Rev Vaccines. 2012 Dec;11(12):1429-40. doi: 10.1586/erv.12.129.
9
Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.
Future Virol. 2012 Apr 1;7(4):371-378. doi: 10.2217/fvl.12.22.
10
A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.
J Virol. 2008 Sep;82(17):8431-41. doi: 10.1128/JVI.00551-08. Epub 2008 Jun 18.
本文引用的文献
1
An attempt to vaccinate against herpes simplex.
Aust J Exp Biol Med Sci. 1950 Sep;28(5):579-84. doi: 10.1038/icb.1950.58.
2
Studies on herpes simplex virus. VI. Observations on patients with recurrent herpetic lesions injected with herpes viruses or their antigens.
Am J Med Sci. 1955 May;229(5):477-85. doi: 10.1097/00000441-195505000-00002.
3
VACCINE THERAPY IN RECURRENT HERPES SIMPLEX.
Arch Dermatol. 1964 Jun;89:844-5. doi: 10.1001/archderm.1964.01590300072021.
4
The value of tissue culture vaccine in the prophylaxis of recurrent attacks of herpetic keratitis.
Am J Ophthalmol. 1962 Aug;54:255-65.
5
Vaccination for recurrent herpes simplex infection; initiation of a new disease site following the use of unmodified material containing the live virus.
AMA Arch Derm. 1956 Jan;73(1):70-1. doi: 10.1001/archderm.1956.01550010072010.
6
The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma.
Gene Ther. 2002 Jan;9(1):75-80. doi: 10.1038/sj.gt.3301620.
7
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.
Gene Ther. 2000 May;7(10):867-74. doi: 10.1038/sj.gt.3301205.
8
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.
Gene Ther. 2000 May;7(10):859-66. doi: 10.1038/sj.gt.3301184.
9
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2208-13. doi: 10.1073/pnas.040557897.
10
Genetically engineered HSV in the treatment of glioma: a review.
Rev Med Virol. 2000 Jan-Feb;10(1):17-30. doi: 10.1002/(sici)1099-1654(200001/02)10:1<17::aid-rmv258>3.0.co;2-g.
Zotero 插件